Tackling Antimicrobial Resistance (AMR) through R&D in novel and existing antimicrobials
This program addresses the critical global health threat of Antimicrobial Resistance (AMR) by funding research and development in novel and existing antimicrobials. It uniquely focuses on reducing the burden of infectious diseases and enhancing health security in sub-Saharan Africa, contributing to the objectives of the AU EU Innovation Agenda and the EU Global Health Strategy.
Who is Funded
This section details the eligibility criteria for applicants, the geographical regions where projects must be implemented, and the overarching objectives of the program. The initiative aims to support collaborative research efforts across EU, associated, and sub-Saharan African countries to combat Antimicrobial Resistance (AMR).
What is Funded
This section outlines the types of projects and thematic areas supported by the program, emphasizing research and development activities in antimicrobials. It specifies the developmental stages of projects that are eligible for funding, ensuring that proposals focus on later-stage clinical research rather than early-stage or preclinical work.
Type and Scope of Funding
This section details the financial mechanisms and limits of the funding program, including the type of financial instrument used, the maximum funding available per project, and general provisions regarding project duration.
Conditions and Requirements
This section outlines the essential conditions and requirements that applicants and beneficiaries must adhere to, covering aspects from application terms and consortium rules to exploitation obligations and reporting.
Application Procedure
This section provides an overview of the application and evaluation process for the funding program, including the two-stage submission model and the criteria used for selection.
Legal Basis
This section identifies the foundational legal and official documents that govern the funding program, providing legitimacy and outlining the framework for its operation.
Similar Programs
Funding Overview
Funding Status:
Closed
Maximum Amount:
6,000,000 €
Allocated Budget:
Total budget for all topics: 136,432,000 EUR. Budget for this topic (HORIZON-JU-GH-EDCTP3-2024-01-04-two-stage) in 2024: 24,000,000 EUR.
Award Channel:
Framework Programme Call
Region:
European Union Member States, Overseas Countries and Territories linked to EU Member States, Horizon Europe Associated Countries, and EDCTP Association Member Countries in Sub-Saharan Africa. There is a strong focus on collaboration with and impact in sub-Saharan Africa.
Sectors:
Healthcare, Medical Technology, Research and Development, Environmental and Climate Protection, Agriculture and Agribusiness
Beneficiaries:
Research institutions, healthcare providers, public health entities, industry partners involved in pharmaceutical development, non-profit organizations.
Application Type:
Consortium Required
Funding Stages:
Experimental Development, Pilot Testing, Product Development, Commercialization, Applied Research
Funding Provider
Program Level:
European Union
Funding Body:
Global Health EDCTP3 Joint Undertaking, European Commission
Managed By:
Global Health EDCTP3 JU
Additional Partners:
Industry partners (involved in development/manufacturing of antimicrobials), Team Europe Initiative on Sustainable Health Security in Africa or Manufacturing and health products (TEI-MAV+), African counterparts (for technology transfer).
Website: